Intel Corporation

Walmart Inc.

Exxon Mobil Corporation

The Boeing Company

Vistra Corp.

Oklo Inc.

General Motors Company

Meta Platforms, Inc.

Novo Nordisk A/S

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

New York morning: pressure on Powell triggers selloffs

LifeMD, Inc.

The telehealth platform will thus expand its partnership with Novo Nordisk

LifeMD to offer Novo Nordisk's Wegovy in oral form; shares jump

Eli Lilly and Company

Viking Therapeutics, Inc.

The best-selling drug from Danish pharmaceutical giant Wegovy is now available in oral form for the first time.

Novo impressed investors by launching a weight loss pill in the US. What are its competitors doing?

RTX Corporation

Rocket Lab Corporation

Alphabet Inc.

First Solar, Inc.

Maplebear Inc.

Morning in New York: macro statistics will set the trading vector

The Danish company's shares have halved in price in 2025 amid doubts about its ability to conquer the market

First obesity pill: US approves Novo drug, how will the market react?

Hanwha Ocean Co., Ltd.

Paramount Skydance Corporation

Warner Bros. Discovery, Inc.

The US Food and Drug Administration (FDA) has approved Novo Nordisk's first semaglutide-based GLP-1 obesity pill, intensifying the company's competition with Eli Lilly. ByteDance, owner of TikTok, plans to invest about $23 billion in AI infrastructure amid record growth in debt financing in the global tech sector. These and other topics - in our review of key events for the morning of December 23.

The main thing for the morning: a pill instead of a shot, ships for the U.S. Navy and $40 billion for Hollywood

Novartis AG

Roche Holding AG

Amgen Inc.

Companies will get a three-year reprieve from pharmaceutical duties, provided they invest in manufacturing within the U.S.

Nine major pharma companies have made deals with Trump to lower drug prices

They are different from the already-hit Wegovy and Zepbound

Lilly and Novo simultaneously filed applications for approval of new obesity drugs

Late-stage trial data also show a potent effect in knee osteoarthritis

Eli Lilly's new drug has helped you lose almost 30% of your weight. It's her weapon of choice against Ozempic

Structure Therapeutics Inc.

Shares of Structure Therapeutics more than doubled on Monday, December 8, closing near $70 apiece, with <a href="https://finance.yahoo.com/quote/GPCR/">the company’s market capitalization</a> rocketing above $4.2 billion. This followed mid-stage trial results for its experimental oral obesity drug, aleniglipron, which <a href="https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-access">delivered</a>&nbsp;greater weight loss than a <a href="https://lilly.mediaroom.com/2025-08-07-Lillys-oral-GLP-1,-orforglipron,-delivers-weight-loss-of-up-to-an-average-of-27-3-lbs-in-first-of-two-pivotal-Phase-3-trials-in-adults-with-obesity">competing pill</a> under development by Eli Lilly. Analysts say the stock may have further upside, particularly if a major player moves to acquire the company.

Structure shares double after 'near-homerun' obesity pill data

NVIDIA Corporation

Apple Inc.

Meta discusses a multi-billion dollar deal to buy Google processors, which increases competition for Nvidia and provokes volatility in its shares. Apple, on the back of a strong iPhone 17 launch and a new round of upgrades, could overtake Samsung to become the global smartphone market leader for the first time in 14 years. Fintech giant Revolut cemented its status as Europe's most expensive startup. The main events of November 24-28 are in our review<b>. </b>